Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H16N2 |
Molecular Weight | 188.2688 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C2CCCCC2=NC3=C1CCC3
InChI
InChIKey=YLUSMKAJIQOXPV-UHFFFAOYSA-N
InChI=1S/C12H16N2/c13-12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12/h1-7H2,(H2,13,14)
DescriptionSources: http://en.medicine-cure.com/ovr2_neyromidin.htmCurator's Comment: description was created based on several sources, including
http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1998.tb00067.x/pdf
Sources: http://en.medicine-cure.com/ovr2_neyromidin.htm
Curator's Comment: description was created based on several sources, including
http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1998.tb00067.x/pdf
Ipidacrine (Neiromidin) is a drug first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. Neuromidin has a direct stimulating effect on the conduct of the pulse along the nerve fibers, interneuronal and neuromuscular synapses of the CNS and peripheral nervous system. Pharmacological action neuromidin is based on a combination of two mechanisms of action: blockade of potassium channels of the membrane of neurons and muscle cells; reversible inhibition of cholinesterase in synapses. Neuromidin enhances the effect on smooth muscle acetylcholine not only, but epinephrine, serotonin, histamine and oxytocin. It has the following pharmacological effects: - Improve and stimulate impulse conduction in the nervous system and neuromuscular transmission; - Enhances contractility of smooth muscle organs under the influence of acetylcholine agonists, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride; - Improves memory, slows progressive course of dementia. In preclinical studies Neuromidin is not teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic action, had no effect on the endocrine system
CNS Activity
Sources: http://en.medicine-cure.com/ovr2_neyromidin.htm
Curator's Comment: Neuromidin (ipidacrine) has a direct stimulating effect on the conduct of the pulse along the nerve fibers, interneuronal and neuromuscular synapses of the CNS and peripheral nervous system.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: http://en.medicine-cure.com/ovr2_neyromidin.htm
Dose and duration of treatment is determined individually depending on the severity of the disease.
Peripheral nervous system diseases: 10-20 mg; 1-3 times a day. The treatment is 1 to 2 months.
To prevent myasthenic crises, severe violations of neuromuscular conduction briefly parenterally administered 1-2 ml (15-30 mg) Neuromidin 1,5% solution for injection, and then continue treatment tablets Neuromidin, the dose can be increased to 20-40 mg; 5 times a day.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66880
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
||
|
WHO-VATC |
QN06DA05
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
||
|
WHO-ATC |
N06DA05
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m776
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
CV71VTP0VN
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
SUB08273MIG
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
C65952
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
DB13668
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
100000083140
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
DTXSID7048299
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
C049860
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
7385
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
4808
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
604519
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
62732-44-9
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL130880
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY | |||
|
Ipidacrine
Created by
admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)